Marijn Dekkers, Bayer
$3.9bn Dekkers allocated $3.9bn to Bayer’s R&D division in 2012, one of the largest in pharmaceuticals $52.8bn Dekkers had a fantastic year with Bayer, making $52.8bn from sales in 2012 Marijn Dekkers describes his business philosophy as being “more innovation, less administration”. Having developed Bayer from an ailing pharmaceutical company to a pioneering corporate model, […]
$3.9bn
Dekkers allocated $3.9bn to Bayer’s R&D division in 2012, one of the largest in pharmaceuticals
$52.8bn
Dekkers had a fantastic year with Bayer, making $52.8bn from sales in 2012
Marijn Dekkers describes his business philosophy as being “more innovation, less administration”. Having developed Bayer from an ailing pharmaceutical company to a pioneering corporate model, Dekkers emphasises the importance of Bayer having focused on new markets and in understanding differences with individual economies. Innovation, for Dekkers, is not achieved with complexity and spending, but through the streamlining of manufacturing and process.
